All 1 tracked stories fall under one category: medical-devices. Oncocyte is most often covered alongside Anbio Biotechnology, which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention Oncocyte, all published on February 22, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Oncocyte
All 1 tracked stories fall under one category: medical-devices. Oncocyte is most often covered alongside Anbio Biotechnology, which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention Oncocyte, all published on February 22, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Oncocyte. Shared-story counts are live from our verified record — not editorial picks.
A comparative analysis of Anbio Biotechnology and Oncocyte reveals a divergence in strategy between high-volume diagnostic manufacturing and specialized precision oncology. As both companies navigate the post-pandemic diagnostic landscape, institutional backing and valuation metrics highlight differing paths toward profitability.